Bristol-Myers Squibb Company
BMYBristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.
Drugs in Pipeline
103
Phase 3 Programs
51
Upcoming Catalysts
6
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
7 upcoming, 3 past
How BMY's past catalysts played out
Irbesartan
Congestive Heart Failure
Deucravacitinib
Plaque Psoriasis
DCV/ASV/BMS-791325
Hepatitis C
Indinavir sulfate
HIV Infections
Entecavir
Chronic Hepatitis B
Peginterferon Lambda-1a
Hepatitis C Virus
Repotrectinib
Carcinoma, Non-Small-Cell Lung
Cetuximab/Erbitux
Head and Neck Cancer
stavudine extended-release, lamivudine, efavirenz
HIV Infections
paclitaxel (PTX)
Breast Cancer
Apixaban
Deep-Vein Thrombosis
Megestrol acetate
Anorexia
Iza-bren
Non-Small Cell Lung Cancer
Tanespimycin
Multiple Myeloma
Lenalidomide
Lymphoma
Apremilast
Psoriasis
Daclatasvir
Hepatitis C
adefovir
Hepatitis B
Xanomeline and Trospium Chloride Capsules
Schizophrenia
Muraglitazar
Diabetes Mellitus
BMS-790052 (Daclatasvir)
Hepatitis C
Entecavir (ETV)
Hepatitis B
Sofosbuvir
Hepatitis C
BMS-986165
Ulcerative Colitis
KarXT
Bipolar-I Disorder With Mania or Mania With Mixed Features
Relatlimab
Lymphoma, Non-Hodgkin
Vinflunine
Bladder Cancer
Abatacept
Nephrotic Syndrome
SAR302503
Hematopoietic Neoplasm
Belatacept
Kidney Transplantation
Asunaprevir
Hepatitis C Virus Infection
BMS-986205
Advanced Cancer
mavacamten
Hypertrophic Cardiomyopathy
KarX-EC
Alzheimer Disease
brivanib
Advanced Non-small Cell Lung Cancer
BMS-986278
Pulmonary Fibrosis
Nivolumab/rHuPH20
Melanoma
Stavudine
AIDS Dementia Complex
NKTR-214
Melanoma
Nivolumab and rHuPH20
Clear Cell Renal Cell Carcinoma
BMS-986489 (BMS-986012+Nivolumab)
Extensive-Stage Small Cell Lung Cancer
Nivolumab 3 mg/kg IV
Melanoma
Intravenous (IV) abatacept
Rheumatoid Arthritis
Milvexian
Ischemic Stroke; Ischemic Attack, Transient
BMS-986504
Pancreatic Ductal Adenocarcinoma
BMS-936558 (Nivolumab)
Melanoma
Pumitamig
Untreated, Unresectable, or Metastatic Colorectal Cancer
Ipilimumab
Prostatic Neoplasms, Castration-Resistant
BMS-986393
Relapsed or Refractory Multiple Myeloma (RRMM)
Ozanimod
Colitis, Ulcerative
Nivolumab
Recurrent Head and Neck Squamous Cell Carcinoma
Procarbazine
Lymphoma
Nivolumab (BMS-936558)
Melanoma
CC-97540
Lupus Erythematosus, Systemic
peginterferon alfa-2a
Hepatitis C Virus
BMS-650032
Chronic Hepatitis C
MDX-010
Prostate Cancer
BMS-986177
Acute Ischemic Stroke
BMS-790052
Hepatitis C Infection
BMS-986178
Advanced Cancer
MDX-060
Hodgkin's Disease
BMS-986213
Gastric Cancer
Elotuzumab (BMS-901608; HuLuc63)
Smoldering Multiple Myeloma
BMS-770767
Dyslipidemia
Elotuzumab
Multiple Myeloma
CTLA4Ig / Abatacept
Psoriasis Vulgaris
Tyrosinase/gp100/MART-1 Peptides
Intraocular Melanoma
Trametinib
Colorectal Cancer
BMS-931699
Lupus
BMS-741672
Neuropathic Pain
BMS-690514
Breast Cancer
Ticagrelor
Coronary Artery Disease
Oral Azacitidine
Acute Myeloid Leukemia
Pomalidomide
Multiple Myeloma
HNO Donor
Heart Failure
BMS-986207
Non-Small Cell Lung Cancer
BMS-986166
Dermatitis, Atopic
BMS-823778
Diabetes Mellitus, Type 2
Pexacerfont
Major Depressive Disorder
BMS-986016
Hematologic Neoplasms
Platinum Doublet Chemotherapy
Non-Small-Cell Lung Cancer
BMS-986408
Advanced Solid Tumors
Anti-IP-10 Antibody
Colitis, Ulcerative
BMS-986179
Malignant Solid Tumor
Luspatercept
Anemia
BMS-817399
Rheumatoid Arthritis
BMS-954561
Post-Herpetic Neuralgia (PHN)
BMS-791325
Chronic Hepatitis C
rHuPH20
Neoplasms by Site
BMS-986158
Advanced Tumors
ipilimumab (MDX-010, BMS-734016)
Melanoma
peg-interferon alfa-2a
Hepatitis C Virus
Cobimetinib
Advanced or Metastatic Solid Tumors
BMS-582949
Rheumatoid Arthritis, NOS
Lirilumab
CANCER,NOS
BMS-986036
Hepatic Cirrhosis
MDX-1100
Ulcerative Colitis
Arlocabtagene Autoleucel
Multiple Myeloma
relatlimab+nivolumab
Melanoma
Cabazitaxel
Metastatic Prostate Neuroendocrine Carcinoma
Ixabepilone
Breast Cancer
Nivolumab + Relatlimab
Melanoma Stage III
Nivolumab 40 mg in 4 ml Injection
Uterine Cervical Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Irbesartan | Phase 3 | Congestive Heart Failure | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
Entecavir | Phase 3 | Chronic Hepatitis B | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus | - | - |
Repotrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Cetuximab/Erbitux | Phase 3 | Head and Neck Cancer | - | - |
stavudine extended-release, lamivudine, efavirenz | Phase 3 | HIV Infections | - | - |
paclitaxel (PTX) | Phase 3 | Breast Cancer | - | - |
Apixaban | Phase 3 | Deep-Vein Thrombosis | - | - |
Megestrol acetate | Phase 3 | Anorexia | - | - |
Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Tanespimycin | Phase 3 | Multiple Myeloma | - | - |
Lenalidomide | Phase 3 | Lymphoma | - | - |
Apremilast | Phase 3 | Psoriasis | - | - |
Daclatasvir | Phase 3 | Hepatitis C | - | - |
adefovir | Phase 3 | Hepatitis B | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
Muraglitazar | Phase 3 | Diabetes Mellitus | - | - |
BMS-790052 (Daclatasvir) | Phase 3 | Hepatitis C | - | - |
Entecavir (ETV) | Phase 3 | Hepatitis B | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
BMS-986165 | Phase 3 | Ulcerative Colitis | - | - |
KarXT | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | - | - |
Relatlimab | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Abatacept | Phase 3 | Nephrotic Syndrome | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Belatacept | Phase 3 | Kidney Transplantation | - | - |
Asunaprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
mavacamten | Phase 3 | Hypertrophic Cardiomyopathy | - | - |
KarX-EC | Phase 3 | Alzheimer Disease | - | - |
brivanib | Phase 3 | Advanced Non-small Cell Lung Cancer | - | - |
BMS-986278 | Phase 3 | Pulmonary Fibrosis | - | - |
Nivolumab/rHuPH20 | Phase 3 | Melanoma | - | - |
Stavudine | Phase 3 | AIDS Dementia Complex | - | - |
NKTR-214 | Phase 3 | Melanoma | - | - |
Nivolumab and rHuPH20 | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
BMS-986489 (BMS-986012+Nivolumab) | Phase 3 | Extensive-Stage Small Cell Lung Cancer | - | - |
Nivolumab 3 mg/kg IV | Phase 3 | Melanoma | - | - |
Intravenous (IV) abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Milvexian | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient | - | - |
BMS-986504 | Phase 3 | Pancreatic Ductal Adenocarcinoma | - | - |
BMS-936558 (Nivolumab) | Phase 3 | Melanoma | - | - |
Pumitamig | Phase 3 | Untreated, Unresectable, or Metastatic Colorectal Cancer | - | - |
Ipilimumab | Phase 3 | Prostatic Neoplasms, Castration-Resistant | - | - |
BMS-986393 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | - | - |
Ozanimod | Phase 3 | Colitis, Ulcerative | - | - |
Nivolumab | Phase 3 | Recurrent Head and Neck Squamous Cell Carcinoma | - | - |
Procarbazine | Phase 2 | Lymphoma | - | - |
Nivolumab (BMS-936558) | Phase 2 | Melanoma | - | - |
CC-97540 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
peginterferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
BMS-650032 | Phase 2 | Chronic Hepatitis C | - | - |
MDX-010 | Phase 2 | Prostate Cancer | - | - |
BMS-986177 | Phase 2 | Acute Ischemic Stroke | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986178 | Phase 2 | Advanced Cancer | - | - |
MDX-060 | Phase 2 | Hodgkin's Disease | - | - |
BMS-986213 | Phase 2 | Gastric Cancer | - | - |
Elotuzumab (BMS-901608; HuLuc63) | Phase 2 | Smoldering Multiple Myeloma | - | - |
BMS-770767 | Phase 2 | Dyslipidemia | - | - |
Elotuzumab | Phase 2 | Multiple Myeloma | - | - |
CTLA4Ig / Abatacept | Phase 2 | Psoriasis Vulgaris | - | - |
Tyrosinase/gp100/MART-1 Peptides | Phase 2 | Intraocular Melanoma | - | - |
Trametinib | Phase 2 | Colorectal Cancer | - | - |
BMS-931699 | Phase 2 | Lupus | - | - |
BMS-741672 | Phase 2 | Neuropathic Pain | - | - |
BMS-690514 | Phase 2 | Breast Cancer | - | - |
Ticagrelor | Phase 2 | Coronary Artery Disease | - | - |
Oral Azacitidine | Phase 2 | Acute Myeloid Leukemia | - | - |
Pomalidomide | Phase 2 | Multiple Myeloma | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986207 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-986166 | Phase 2 | Dermatitis, Atopic | - | - |
BMS-823778 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Pexacerfont | Phase 2 | Major Depressive Disorder | - | - |
BMS-986016 | Phase 2 | Hematologic Neoplasms | - | - |
Platinum Doublet Chemotherapy | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
BMS-986408 | Phase 2 | Advanced Solid Tumors | - | - |
Anti-IP-10 Antibody | Phase 2 | Colitis, Ulcerative | - | - |
BMS-986179 | Phase 2 | Malignant Solid Tumor | - | - |
Luspatercept | Phase 2 | Anemia | - | - |
BMS-817399 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-954561 | Phase 2 | Post-Herpetic Neuralgia (PHN) | - | - |
BMS-791325 | Phase 2 | Chronic Hepatitis C | - | - |
rHuPH20 | Phase 2 | Neoplasms by Site | - | - |
BMS-986158 | Phase 2 | Advanced Tumors | - | - |
ipilimumab (MDX-010, BMS-734016) | Phase 2 | Melanoma | - | - |
peg-interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Cobimetinib | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
BMS-582949 | Phase 2 | Rheumatoid Arthritis, NOS | - | - |
Lirilumab | Phase 2 | CANCER,NOS | - | - |
BMS-986036 | Phase 2 | Hepatic Cirrhosis | - | - |
MDX-1100 | Phase 2 | Ulcerative Colitis | - | - |
Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma | - | - |
relatlimab+nivolumab | Phase 2 | Melanoma | - | - |
Cabazitaxel | Phase 2 | Metastatic Prostate Neuroendocrine Carcinoma | - | - |
Ixabepilone | Phase 2 | Breast Cancer | - | - |
Nivolumab + Relatlimab | Phase 2 | Melanoma Stage III | - | - |
Nivolumab 40 mg in 4 ml Injection | Phase 2 | Uterine Cervical Neoplasms | - | - |
multiple myeloma
3 drugs in this indication
Alzheimer's
1 drug in this indication
Lupus Erythematosus, Systemic
1 drug in this indication
advanced melanoma
1 drug in this indication
blood cancer
1 drug in this indication
Duchenne muscular dystrophy
1 drug in this indication
multiple myeloma (relapsed or refractory)
1 drug in this indication
Relapsed/Refractory Multiple Myeloma
1 drug in this indication
Alzheimer's psychosis
1 drug in this indication
advanced hepatocellular carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bristol-Myers Squibb Company's drug pipeline?→
CatalystAlert tracks 103 drug candidates in Bristol-Myers Squibb Company's (BMY) pipeline across Phase 3, Phase 2. Its lead program is Irbesartan (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bristol-Myers Squibb Company's next FDA catalyst?→
Bristol-Myers Squibb Company's (BMY) next tracked catalyst is a Phase 3 expected November 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BMY biotech catalysts?→
Add BMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bristol-Myers Squibb Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.